← Back to Search

Small Molecule Drug

Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days) for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Hossein Borghaei, DO
Research Sponsored by Fox Chase Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial tests sotorasib, an oral medication, in newly diagnosed patients with stage Ib-IIIa NSCLC who have a KRAS G12C mutation. The drug aims to shrink tumors by blocking growth signals in cancer cells. Sotorasib is the first FDA-approved targeted therapy for KRAS G12C-mutated non-small cell lung cancer (NSCLC).

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Major pathologic response
Secondary study objectives
Determine the safety, feasibility and tolerability of neoadjuvant sotorasib therapy in patients with surgically resectable KRAS G12C mutant NSCLC

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Fox Chase Cancer CenterLead Sponsor
234 Previous Clinical Trials
39,373 Total Patients Enrolled
Hossein Borghaei, DOPrincipal InvestigatorFox Chase Cancer Center
3 Previous Clinical Trials
93 Total Patients Enrolled
~0 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top